For this we utilize a patient-derived tumor organoid (P18T) with loss-of-function mutations in the WNT (APC) and TP53 pathway, but that is wild type for the RAS pathway and as such requires EGF-mediated growth factor signaling for growth and survival [50]. Here, TP53 is linked to neoplasm.